Chiropractic + Naturopathic Doctor

News
Industry News – Theralase cancer therapy trials


March 10, 2011
By Maria DiDanieli

Feb. 28, Toronto, Ont. – Theralase Technologies Inc. announced today that it has successfully completed the pre-clinical safety testing, in an in vivo mouse model, of its innovative Photo Dynamic Compound (PDC) platform technology.

Feb. 28, Toronto, Ont. – Theralase Technologies Inc. announced today that it has successfully completed the pre-clinical safety testing, in an in vivo mouse model, of its innovative Photo Dynamic Compound (PDC) platform technology.

The Theralase patented PDC's comprise a family of novel drug candidates under evaluation from the company's proprietary PDC inventory focused on oncological indications.

Advertisement

Lothar Lilge Ph.D., the principal investigator of the Theralase PDC cancer compound technology at the Ontario Cancer Institute of the renowned Princess Margaret Hospital, University Health Network stated that, "For the four lead PDCs under investigation the Mean Tolerated Dose (MTD) was determined in an established in-vivo pre-clinical safety model and was well tolerated by animals at levels comparable to and above that of other FDA approved photosensitizers. Results demonstrate that the observed MTD was ten times higher than clinical doses of photosensitizers currently employed in medical practice. This provides the basis of a strong safety and tolerability profile of the patented Theralase PDCs.

It also provides the required data to allow our research to proceed to the next stage; specifically, the determination of the effectiveness of the Theralase PDCs in the selective destruction of cancerous tumours growth and metastatic spread, while preserving normal tissue. We will also evaluate skin photosensitivity and the tissue selectivity of the PDCs to cancer versus normal tissue structures during treatment. I am encouraged by the results achieved to date and my team looks forward to establishing the efficacy of the Theralase PDCs in these established cancer models, as our research progresses."

Roger Dumoulin-White, President and CEO of Theralase Inc. stated that, "We are delighted that our research into these cancer killing PDCs has progressed to where we can introduce them safely and tolerably at very high doses into live animals. This is the crucial step in evaluating Theralase's anti-cancer technology in an in vivo preclinical MTD model that lays the groundwork for proving the application of the first generation of Theralase's patented platform technology for advanced anti-cancer therapy.

If proven successful in the next set of animal preclinical cancer models, we will be able to undertake early discussions with the FDA and Health Canada on using our patented PDCs to destroy cancer in cats, dogs and horses, followed by the evaluation of the PDCs in human subjects in a Phase I human clinical trial."

For more information visit the corporate or regulatory website at www.theralase.com or www.sedar.com